Dynavax Technologies | DVAX - Ordinary Share Capital



Dynavax Technologies reported $117.23M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Adma Biologics USD 238.57M 238.54M Jun/2025
Amgen USD 538M 33.04B Jun/2025
AstraZeneca USD 1.55B 1.16B Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
Merck USD 1.79B 0 Mar/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Novartis USD 793M 0 Dec/2024
Pfizer USD 5.68B 5.2B Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Roche Holding CHF 107M 0 Jun/2024
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
TG Therapeutics USD 158.02M 157.87M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025